Dipeptidyl peptidase-4 (DPP-4) inhibitors are a relatively new class of oral diabetes drugs. Also known as gliptins, they are usually prescribed for people with type 2 diabetes who have not responded ...

DPP-4 exists as both a membrane-bound and soluble form. DPP-4 has historically been associated with its capacity to metabolize incretin hormones. Recent studies have identified additional functions of ...

Dipeptidyl peptidase-4 (DPP-4) inhibitors, commonly used to treat high blood glucose, have also shown efficacy against low blood sugar levels in a recent study. Results from this study have been ...

MELBOURNE, Australia — Patients with type 2 diabetes who are at high risk for or who already have heart failure should not be precluded from receiving dipeptidyl peptidase-4 (DPP-4) inhibitor ...

Findings from a study published in Acta Diabetologica support that treatment with dipeptidyl peptidase-4 (DPP-4) inhibitors is associated with better vitamin D balance in patients with type 2 diabetes ...

A Policy article in the May issue of The American Journal of Managed Care® suggests that sequential addition of SGLT2 inhibitors to DPP-4 inhibitors may be considered cost-effective compared with ...

In September, Indian drug manufacturer Alembic received a tentative nod from the US Food and Drug Administration (FDA) to manufacture generic alogliptin as well as the alogliptin/metformin fixed-drug ...

Last year, an FDA advisory panel called for an updated label for saxagliptin, but the agency is still gathering information. An analysis of claims data found no association between the use of DPP-4 ...

The whole world has been shaken by the COVID-19 pandemic. Scientists working in different fields such as epidemiology, virology and immunology are struggling to find the remedy to control and prevent ...